What if the industry develops highly effective cancer treatments and no one pays for them? BusinessWeek takes on the question in a reasonably savvy brief article this week. A sample:
“At some point—and that point will come sooner rather than later—payers are not going to approve spending $100,000 for someone to live an extra six months,” [...]

[Read more →]

Lilly broke the news Monday morning that ImClone had accepted its offer to acquire the biotech firm for $6.5 billion or $70 per share—Lilly’s largest acquisition ever.
With this purchase Lilly gains control of ImClone’s blockbuster, targeted cancer agent Erbitux, which is marketed for second- and third-line colon cancer and refractory head and neck cancer.
ImClone also [...]

[Read more →]